FyMed, Inc.

Press Releases
naproxen

FY103B Identified to Exhibit Profound Antineoplastic Effects in the Digestive Tract

Researchers at FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, have identified novel antineoplastic benefits from FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. Read More...

FyMed Announces Top-Line Results Demonstrating Superiority of FY103B over Celecoxib in the Treatment of Pain and Inflammation

FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety. Read More...

FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen In the Treatment of Pain and Inflammation

FyMed, Inc. today announced results from comparative in-vivo studies of FY101C, its lead NSAID candidate, which demonstrated significant superiority to conventional NSAIDs in terms of efficacy and safety in the management of acute and chronic pain and inflammation. Read More...